Imaging Agents Market is Predicted to Reach US$ 10.3 Billion by 2035, Expanding at a CAGR of 7% | Fact.MR

The worldwide imaging agents market is anticipated to be valued at USD 5.2 billion in 2025. With a CAGR of 7.0% between 2025 and 2035, the valuation of the industry is anticipated to reach USD 10.3 billion by the end of the forecast period.

It is driven most by a growth in demand for advanced diagnostic imaging for oncology, cardiology, and neurology and by higher investment in molecular imaging and precision diagnostics. North America takes the lead as it has established diagnostic infrastructure and high per capita healthcare expenditures.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7775

Country-wise analysis

USA imaging agents market is expected to grow at 6.9% CAGR during the forecast period. Growing instances of chronic conditions and the aging population are primarily fueling demand for diagnostic imaging tests. Increased expenditure on healthcare infrastructure and utilization of advanced imaging modalities such as PET, MRI, and CT scans are stimulating growth in the imaging agents market.

The UK market for imaging agents will expand at 6.3% CAGR during the study period. Growing demand for accurate and early-stage diagnostic imaging in oncology, neurology, and cardiology is propelling the consumption of visualization agents in the UK. Convergence of technology between National Health Service (NHS) organizations is increasing diagnostic capabilities with increased reliance on contrast-enhanced imaging techniques. Presence of robust research facilities and supportive regulatory environments for radiopharmaceuticals are fuelling innovation in the industry.

The German imaging agents market is anticipated to exhibit a 6.5% CAGR during the study period. Strong diagnostic infrastructure, large healthcare spending, and extensive clinical research render Germany a significant imaging agent market. The prevalence of chronic disease and focus on early diagnosis has significantly driven imaging procedure volume expansion.

The South Korean imaging agents market is predicted to grow at 6.6% CAGR over the years encompassed in this study. Being endowed with an advanced healthcare system and deep penetration of technology, South Korea is experiencing growth in the use of imaging diagnostics. Demand is being fueled mainly by cancer diagnosis, neurological disorders, and cardiovascular disease. Government promotion of precision medicine and radiology is fueling the development and marketing of new imaging agents.

Segment-wise Analysis

By Modality

By 2025, the worldwide market for imaging agents is expected to see a huge share of nearly 32% attributed to diagnostic radiopharmaceuticals and 25%left for imaging agents using X-rays.

By Product

Iodinated Contrast Media will control the Imaging Agents Market in the year 2025 with a share of 40%, followed by Gadolinium-based Contrast Media with about 25%.

Competitive Outlook

The market for imaging agents is experiencing high levels of innovation in molecular imaging and theranostics, with all the leaders building their radiopharmaceuticals and contrast media portfolios. GE Healthcare will continue to lead the global platform with its program of integrated diagnostics and growing PET and SPECT tracer capabilities through in-house development and partnership.

Bayer Healthcare Pharmaceuticals is also performing well against robust gadolinium-based contrast agents and MRI solutions with an emphasis on AI-powered diagnosis and augmentation in radiological workflows. Bracco Diagnostics, Inc. maintains industry leadership with investments in R&D strategies to build its iodinated and gadolinium agent pipelines and active alliances for next-generation imaging technologies.

Besides that, Curium is advancing as a leading force in nuclear medicine, particularly with SPECT and PET-designed procedures, reinforcing further radiopharmaceutical supply chains in Europe and in the USA Lantheus Medical Imaging, Inc. is also taking its opportunity from a fast demand trend of precision diagnostics with its so-called fluorinated agents along with imaging products for prostate cancer, such as Pylarify.

Browse Full Report: https://www.factmr.com/report/imaging-agents-market

Key Players

GE Healthcare
Eli Lilly
Bayer Healthcare Pharmaceuticals
Alliance Medical
Bracco Diagnostics, Inc.
Aytu BioScience, Inc.
Curium
Guerbet Group
Lantheus Medical Imaging, Inc.
Trivitron Healthcare
Beijing Beilu Pharmaceutical Co Ltd.

Segmentation

By Modality:
Diagnostic Radiopharmaceuticals
X-ray
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Ultrasound
Others
By Product:
Iodinated Contrast Media
Gadolinium-based Contrast Media
Microbubble Contrast Media
Barium-based Contrast Media
By Application:
Oncology
Cardiology
Gastrointestinal
Neurology
Others
By End User:
Hospitals
Ambulatory Surgical Centers
Diagnostic & Imaging Centers
Others
By Region:
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA

Check out More Related Studies Published by Fact.MR:

Body Composition Analyzers Market
https://www.factmr.com/report/body-composition-analyzers-market
Beta Interferon Market
https://www.factmr.com/report/beta-interferon-market
ECG Cable and ECG Lead Wires
Market https://www.factmr.com/report/ecg-cable-and-ecg-lead-wires-market
Portable Isolation Room Market
https://www.factmr.com/report/portable-isolation-room-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.